Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Populares anti谩cidos, 驴podr铆an causar da帽o a los ri帽ones?
Una nueva investigaci贸n ha vinculado a los PPI, con graves efectos secundarios, incluyendo enfermedad renal cr贸nica, y demandas presentadas recientemente alegan que los que producen la droga deber铆an haber sabido sobre sus da帽os potenciales.
Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won鈥檛 be.聽
Nearly 1 In 3 Recent FDA Drug Approvals Followed By Major Safety Actions
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, 鈥渂lack box鈥 warnings or other actions.
Drugmakers Dramatically Boosted Lobbying Spending In Trump鈥檚 First Quarter
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump鈥檚 Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump鈥檚 inauguration, which earned them entry into private events with the president and vice president.
By The Numbers: Trump’s Choice For FDA Chief Is Versatile, Entrenched In Pharma
The numbers show that President Trump鈥檚 choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
Making Multiple Drugs In One Factory Risks Scary Side Effect Of Shortages
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
Drugmaker Marathon 鈥楶ausing鈥 Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Six U.S. Senators Confronting Trump鈥檚 HHS Cabinet Pick Own Health Care Stocks, Too
Donald Trump鈥檚 pick to run HHS has been under fire for trading health care stocks but at least six senators at his confirmation hearings also own such stocks.
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Una investigaci贸n de Kaiser Health News analiza las acciones de compa帽ias farmac茅uticas para manipular los precios de medicamentos hu茅rfanos, utilizados para tratar enfermedades raras.
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren鈥檛 new or were repurposed multiple times, an investigation shows.
Los ganadores y los perdedores del 21st Century Cures Act
El 21st Century Cures Act que firm贸 el presidente Barack Obama el martes 13 de diciembre es un 茅xito legislativo para la industria farmac茅utica. Qu茅 podr铆a pasar con los servicios de medicina preventiva.
Grab Bag Of Goodies In 21st Century Cures Act
A breakdown of winners 鈥 and a few losers 鈥 in the sprawling Cures Act approved by the House.
A Frenzy Of Lobbying On 21st Century Cures
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
